Rebamipide in Recurrent Aphthous Stomatitis: Review of Indian Evidence

Abstract

Recurrent aphthous stomatitis (RAS) is one of the commonly observed disease of the oral cavity and the prevalence ranges from 5 to 60%. Despite its high prevalence, the exact pathophysiology of the disease remains unknown. Multiple etiologic factors, followed by three stages of the disease, and types based on severity, with addition of pain and inflammation makes the management challenging for the clinician. A number of drugs are available for the treatment having their own advantages and limitations. In this narrative review, we review the available Indian evidence with Rebamipide in RAS. Indian clinical evidence
clearly establishes the safety and efficacy of rebamipide in the management of RAS. Thus, considering the benefits of reduced duration of pain, accelerated healing and decreased recurrence, we conclude that the current Indian evidence supported by our clinical experience establishes the role of Rebamipide in RAS. Hence, we recommend Rebamipide may be considered as a first line treatment option in RAS.
Conflict of Interest: Ashwin Kotamkar, Aaditi Phadke, Parthasarathy Muralidharan and Amit Qamra are salaried employees of Macleods Pharmaceuticals Ltd., Mumbai, India. Other authors declare no conflict of interest.